 |
|||||||||
   |
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Elizabeth Davis, PhD
Education: Laura J. Mauro, Elizabeth A, Olmsted, Alan R. Davis, and Jack E. Dixon (1995) PTH Regulates the Expression of the Receptor Protein Tyrosine Phosphatase OST-PTP, in Rat Osteoblast-Like Cells, Endocrinology 137:925-933. E. A. Olmsted-Davis, F. H. Gannon, M. Ozen, M. M. Ittmann, Z. Gugala, J. A. Hipp, K. M. Moran, C. Fouletier-Dilling, S. Schmura-Martin, R. W. Lindsey, M. H. Heggeness, M. K. Brenner and A. R. Davis (2007) Hypoxic Adipocytes Pattern Early Heterotopic Bone Formation Am J Path 170:620-632. Jessica Shafer, Alan R. Davis, Francis H. Gannon, Christine Fouletier-Dilling, ZaWaunyka Lazard, Kevin Moran, Zbigniew Gugala, Mustafa Ozen, Michael Ittmann, Michael H. Heggeness, and Elizabeth Olmsted-Davis. Bone Tissue Engineering: A Model for Delineating the Early Events in Endochondral Bone Formation. (Tissue Engineering, In Press 2007). Malavosklish Bikram, Christine Fouletier-Dilling, John A, Hipp, Francis Gannon, Alan R. Davis, Elizabeth A. Olmsted-Davis, and Jennifer L. West. Endochondral Bone Formation from Hydrogel Carriers Loaded with BMP2-Transduced Cells. (Annals of Biomedical Engineering, In Press 2007). C. Fouletier-Dilling, F. Gannon, E.A. Olmsted-Davis, Z. Lazard, M. Heggeness, J.A. Shafer, J.A. Hipp, and A.R. Davis. Efficient and Rapid Osteoinduction in an Immune Competent Host. (Human Gene Therapy, In revision).
Department of Pediatrics
Section of Hematology-Oncology,
Baylor College of Medicine
Contact Information:
edavis@bcm.edu
713-798-1253
Dr. Olmsted-Davis’s research program encompasses the design of a cell based gene therapy system for targeted production of bone. One of the therapeutic goals for this system is to enhance bone repair both in long bone fractures, as well as offer a potential treatment for critical size defects resulting from bone trauma. These clinical problems are difficult challenges to orthopedic surgeons resulting in the need to introduce additional hardware or bone graft, and often in the case of trauma, result in the loss of the limb altogether. Our system is designed to rapidly form bone within two weeks after a single injection of our gene therapy system, thus significantly reducing both complications from potential infection as well as overall recovery time. This work is currently supported by the DOD-orthopedic trauma research program.
A second approach for the treatment of critical size defects is to tissue engineer the bone within a bioreactor which could then later be engrafted into the defect area. This work is a collaborative effort between our laboratory and several others within the Center for Cell and Gene Therapy, and Baylor College of Medicine. Our contribution to this project is to characterize the normal physiological processes of de novo bone formation. Using our gene therapy model, we have identified a novel stem cell population and characterized the micro-environmental signals that eventually lead to stem cell differentiation into cartilage and bone. This work is currently funded by the NIBIB.
The third focus of the laboratory is to develop a non-invasive approach for spine fusion. This project has been ongoing over the past three years and has resulted in an efficacious injectable system that results in fusion of the vertebral bones. We are currently completing the efficacy testing in rodent models. Once animal testing is completed, we propose to translate this project into a tentative clinical trial. This work is supported by the DOD-PRMRP.
Dr. Olmsted-Davis has also been involved with establishing a Vector Development Laboratory, a non-profit core facility at Baylor College of Medicine, which provides gene therapy vectors for use as gene delivery systems for preclinical and basic research. This organization has aided researchers in both the Texas Medical Center as well as the global research community.
Selected Publications:
Laura J. Mauro, Elizabeth A. Olmsted, Beverley M. Skrobacz, Robert J. Mourey, Alan R. Davis, Jack E. Dixon (1994) Identification of a Hormonally-Regulated PTPase Associated with Bone and Testicular Differentiation, J Biol Chem 269:30659-30667.
Francis H. Gannon, Frederick S. Kaplan, Elizabeth A. Olmsted, Gerald C. Finkel, Michael Zasloff, and Eileen Shore (1996) Bone Morphogenetic Protein 2/4 in Early Fibromatous Lesions of Fibrodysplasia Ossificans Progressiva. Human Path 28:339-343.
Elizabeth A. Olmsted, Francis H. Gannon, Zhao-Qi Wang, Agamemnon E. Grigoriadis, Erwin Wagner, and Frederick S. Kaplan (1998) Embryonic Over-expression of the c-Fos Proto-Oncogene: A Murine Stem Cell Chimera Applicable to the study of Fibrodysplasia Ossificans Progressiva in Humans. Clinic Ortho Rel Res 346:81-95.
Thomas F. Lanchoney, Elizabeth A. Olmsted, Vicki Rosen, Michael Zasloff, Eileen M. Shore, and Frederick S. Kaplan (1998) Characterization of BMP-4 Receptor Expression in Fibrodysplasia Ossificans Progessiva. Clinic Ortho Rel Res 346:38-46.
George L. Yeh, Sameer Mathur, Ashley Wivel, Ming Li, Elizabeth A. Olmsted, Francis H. Gannon, Angels Ulied, Laura Audi, Frederick S. Kaplan, and Eileen M. Shore (2000) GNAS1 mutation and cbfa1 misexpression in a child with severe congenital plate-like osteoma cutis: A variant of progressive ossesous heteroplasia. J Bone Miner Res 15:2063-2073.
Elizabeth A. Olmsted-Davis, Jeremy S. Blum, Donna Rill, Patricia Yotnda, Zbigniew Gugala, Ronald W. Lindsey, Alan R. Davis (2001) Adenovirus-Mediated BMP2 Expression in Human Bone Marrow Stromal Cells. J Cell Biochem 82:11-21.
Elizabeth A. Olmsted-Davis, Zbigniew Gugala, Francis Gannon, Patricia Yotdna, Robert McAlhany, Ronald Lindsey, and Alan R. Davis (2002) Use of a Chimeric Adenovirus Vector Enhances BMP2 Production and Bone Formation. Hum Gene Ther 13:1337-1347.
Elizabeth A. Olmsted, Frederick S. Kaplan, and Eileen M. Shore (2003) Mechanisms Controlling Bone Morphogenetic Protein 4 Message Expression in Fibrodysplasia Ossificans Progressiva. Clinic Ortho Rel Res 408:331-343.
Zbigniew Gugala, Elizabeth A. Olmsted-Davis, Francis H. Gannon, Ronald W. Lindsey, and Alan R. Davis (2003) Osteoinduction by Ex Vivo Adenovirus-Mediated BMP2 Delivery Is Independent of Cell Type. Gene Ther 10(16):1289-1296.
Elizabeth A. Olmsted-Davis , Zbigniew Gugala, Fernando Carmargo, Francis H. Gannon, KathyJo Jackson, Kirsten Anderson Kienstra, H. David Shine, Ronald W. Lindsey, Karen K. Hirschi, Maragaret A. Goodell, Malcolm A. Brenner, and Alan R. Davis (2003). Primitive Adult Hematopoietic Stem Cells Can Function as Osteoblast Precursors. Proc Natl Acad Sci USA 100(26):15877-15882.
R. Dacquin, P.J. Mee, J. Kawaguchi, E. Olmsted-Davis , J. Gallagher, J. Nichols, K. Lee, G. Karsenty and A. Smith (2004). Knock-in of nuclear localised ß-galactosidase reveals that the tyrosine phosphatase Ptprv is specifically expressed in cells of the bone collar. Dev Dynamics 229:826-34.
Christine Fouletier-Dilling, Pablo Bosh, Alan R. Davis, Jessica Shafer, Steven Stice, Zbigniew Gugala, Francis H. Gannon, and Elizabeth A. Olmsted-Davis (2005). A Novel Compound Enables High-Level Adenovirus Transduction in the Absence of an Adenovirus-Specific Receptor. Human Gene Therapy 16(11): 1287-1298.
©2002,
Cell And Gene Therapy, Baylor College
of Medicine
One Baylor Plaza, N1002, Houston, TX 77030, (713)798-1246
URL: http://www.bcm.edu/genetherapy
Email:cagt@bcm.edu
(Modified:August 15, 2006- SM)
